Mindbio Therapeutics Corp. (TSE:MBIO) has released an update.
MindBio Therapeutics Corp. is making significant strides in the field of psychedelic medicine, having completed early clinical trials with promising results for its proprietary LSD-based treatment for depression, and is now in the midst of Phase 2B trials. The company is also preparing for Phase 3 trials and is considering a dual listing on a senior exchange in the US or Australia to further support its growth. MindBio stands out as a leader on the Canadian Securities Exchange for its advanced stage in clinical trials for psychedelic medicines and is actively engaging with investment groups for potential expansion.
For further insights into TSE:MBIO stock, check out TipRanks’ Stock Analysis page.
